Company Analysis

Kazia Therapeutics Limited (KZIA)

Nasdaq: KZIA · Pharmaceutical Preparations · filing with the SEC since 2002
Grade3.0
◀ Past 2.8● Present 2.5▶ Future 3.6
2 est.

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

1 patent granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Kazia Therapeutics Limited’s names, not what it holds today.

Patents granted
1
1 utility, 1976 to Dec 31, 2025
Granted in 2025
none
in the last year the record reads
Applications published
6
since 2001, to Dec 31, 2025
Names they are printed under
2
a former name, its own name
By yearGrantedApplications published
'16'17'18'19
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
Under which name2 counted
Novogen Limited a former name
named as the applicant on its applications, in AU
0 granted
6 published
Kazia Therapeutics Limited its own name
AU, as the owner printed on each patent
1 granted
0 published
Names not counted (1)
NOVOGEN LTD
Most of its patents print US; this name counts in AU. 5 granted and 2 published under it are not counted.
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Aug 6, 201910,370,349Functionalised benzopyran compounds and use thereofOrganic fine chemistryKazia Therapeutics Limited
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
May 24, 20182018/0141925FUNCTIONALISED BENZOPYRAN COMPOUNDS AND USE THEREOFOrganic fine chemistryNovogen Limited · patent 10,370,349 granted from it
Jun 15, 20172017/0166555FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTSOrganic fine chemistryNovogen Limited
Jun 8, 20172017/0158636FUNCTIONALISED AND SUBSTITUTED CARBAZOLES AS ANTI-CANCER AGENTSOrganic fine chemistryNovogen Limited
Jun 8, 20172017/0157135FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTSOrganic fine chemistryNovogen Limited
Jun 1, 20172017/0152226FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTSPharmaceuticalsNovogen Limited
Nov 24, 20162016/0340329FUNCTIONALISED BENZOPYRAN COMPOUNDS AND USE THEREOFOrganic fine chemistryNovogen Limited · patent 9,701,655 granted from it

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton KZIA · research, not advice